XYD129 is a Promising CBP/p300 Degrader (MV4-11 Cells, IC50 = 49 nM; MOLM-16 Cells IC 50 =7.4 nM). XYD129 for the Treatment of Acute Myeloid Leukemia. XYD129 demonstrated high potency and formed a ternary complex between CBP/p300 and CRBN (AlphaScreen). The compound effectively degraded CBP/p300 proteins and exhibited greater inhibition of growth in acute leukemia cell lines. XYD129 demonstrated significant inhibition of tumor growth in a MOLM-16 xenograft model (TGI = 60%) at tolerated dose schedules.
MedKoo Cat#: 127142
Name: XYD129
CAS#: N/A
Chemical Formula: C41H39FN8O9
Exact Mass: 806.2824
Molecular Weight: 806.81
Elemental Analysis: C, 61.04; H, 4.87; F, 2.35; N, 13.89; O, 17.85
The following data is based on the product molecular weight 806.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
